AIDS Drug Assistance Programs

One of the Largest HIV Privacy Breach Payments Arriving in Mailboxes This Week, says Consumer Watchdog

Retrieved on: 
Tuesday, December 19, 2023
Family, Risk, Multimedia, Friends, LLP, Consumer Watchdog, The American Lawyer, AIDS, Holiday, Disease, Social stigma, California Department, AIDS Drug Assistance Programs, Lawyer, History, Health insurance, Spring Street Courthouse, Privacy, Name, Lawsuit, Identity theft, Insurance, Anxiety, The National Law Journal, HIV, Patient, Diagnosis, Employment, Public health, CDPH, Pharmacy

The payment is part of the settlement of a class-action lawsuit brought on behalf of a "John Doe" plaintiff by lawyers for the non-profit Consumer Watchdog and Whatley Kallas, LLP.

Key Points: 
  • The payment is part of the settlement of a class-action lawsuit brought on behalf of a "John Doe" plaintiff by lawyers for the non-profit Consumer Watchdog and Whatley Kallas, LLP.
  • As alleged in the lawsuit, an employee of an organization contracted with the state of California illegally disclosed personal medical information to several health-related organizations.
  • The personal and medical information allegedly released in the breach included, names, dates of birth, personal phone numbers and email addresses, HIV statuses, and other medical conditions.
  • 'HIV stigma and discrimination can pose complex barriers to prevention, testing, treatment, and support for people living with or at risk for HIV.'"

Celltrion USA Launches Yuflyma® (adalimumab-aaty), a Humira® (adalimumab) biosimilar, in the United States

Retrieved on: 
Monday, July 3, 2023
Oncology, FDA, Health, Clinical Trials, General Health, Biotechnology, AIDS Drug Assistance Programs, University of Massachusetts, Ankylosing spondylitis, Nursing, Ulcerative colitis, Psoriasis, Juvenile idiopathic arthritis, Food and Drug Administration Amendments Act of 2007, Patient, PAP, Biosimilar, Celltrion, Food, Rheumatoid arthritis, Pharmaceutical industry, Adalimumab

Celltrion USA today announced the launch of Yuflyma® (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar, providing an alternative option for patients.

Key Points: 
  • Celltrion USA today announced the launch of Yuflyma® (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar, providing an alternative option for patients.
  • “We are committed to providing a patient-centric approach with a focus on increased access to innovative, high-quality biologics in the United States.
  • Patients who are uninsured or underinsured may be eligible to receive Yuflyma through the Celltrion CONNECT® Patient Assistance Program (PAP).
  • Celltrion is seeking an interchangeability designation from the U.S. FDA for Yuflyma, tentatively expected Q4 in 2024.

MISTR EXPANDS TELEHEALTH PLATFORM TO INCLUDE LONG-TERM HIV CARE

Retrieved on: 
Thursday, December 1, 2022
Viral load, Telehealth, Human, ADAP, Pharmacist, Insurance, Patient, AIDS Drug Assistance Programs, Andrew Kohut, HIV, Infection, PAP, ART, Pharmaceutical industry, Health insurance

NEW YORK, Dec. 1, 2022 /PRNewswire/ -- MISTR, the telehealth platform built to provide free and discreet online access to pre-exposure prophylaxis (PrEP), has expanded its offering to include long-term HIV treatment. Through MISTR, people who test positive for HIV will now be able to connect virtually with a physician and build a long-term care plan with no out-of-pocket costs or in-office doctors' appointments. MISTR's free online PrEP and HIV services are available in all 50 states, D.C. and Puerto Rico.

Key Points: 
  • Through MISTR, people who test positive for HIV will now be able to connect virtually with a physician and build a long-term care plan with no out-of-pocket costs or in-office doctors' appointments.
  • MISTR is a company designed specifically to serve gay and bisexual men, a population disproportionately impacted by HIV.
  • With the introduction of long-term HIV care, MISTR now offers two options for reducing the spread of the virus: PrEP and antiretroviral therapy (ART).
  • MISTR is a telemedicine platform offering easy online access to pre-exposure prophylaxis (PrEP) and long-term HIV care in all 50 states, D.C. and Puerto Rico.

ADAP Advocacy Association Spearheads National Campaign to Protect Ryan White HIV/AIDS Program

Retrieved on: 
Monday, August 15, 2022
HIV/AIDS, Association, Multimedia, Public health, House Committee, White, AIDS Drug Assistance Programs, HELP, Congress, Ryan, Commerce, Government, Labour, United States Senate Committee on Commerce, Science, and Transportation, Patient, Education, Program, Central Laborers' Pension Fund v. Heinz, Energy, Awareness, ADAP, United States Senate Committee on Health, Education, Labor and Pensions, AIDS, HIV, Ranking, Person, Health insurance, Pharmaceutical industry, Health

WASHINGTON, Aug. 15, 2022 /PRNewswire/ -- The ADAP Advocacy Association today submitted a sign-on letter to Congress expressing the HIV Community's collective concerns over the Ryan White PrEP Availability Act (S.4395). The sign-on letter – which was endorsed by nearly 100 national, state, and local organizations – is part of a national campaign to protect the Ryan White HIV/AIDS Program (RWHAP), namely opposing efforts to raid the program to fund pre-exposure prophylaxis.

Key Points: 
  • WASHINGTON, Aug. 15, 2022 /PRNewswire/ -- The ADAP Advocacy Association today submitted a sign-on letter to Congress expressing the HIV Community's collective concerns over the Ryan White PrEP Availability Act (S.4395).
  • The sign-on letter which was endorsed by nearly 100 national, state, and local organizations is part of a national campaign to protect the Ryan White HIV/AIDS Program (RWHAP), namely opposing efforts to raid the program to fund pre-exposure prophylaxis.
  • To learn more about the ADAP Advocacy Association , AIDS Drug Assistance Programs, or S.4395, please email [email protected].
  • About the ADAP Advocacy Association: The ADAP Advocacy Association mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improves access to care for persons living with HIV/AIDS.

Magellan Rx Management’s AIDS Drug Assistance Program Center of Excellence Expands Program That Significantly Improves Medication Adherence and Quality of Care for Patients with HIV

Retrieved on: 
Wednesday, September 15, 2021
General Health, AIDS, Health, Pharmaceutical, Clinical Trials, Knowledge, Health, Health Resources and Services Administration, Program, Education, MGLN, HIV/AIDS, Technology, Navigation, Art therapy, Center, BMJ Open, Depression, ADAP, Systematic review, Patient, HRSA, HIV, Viral load, Disease, NASDAQ, Ferdinand Magellan, MD, Trade, ART, COE, State, Person, Pharmacy, Adap Galo Maringá Football Club, AIDS Drug Assistance Programs, Fall Prevention Center of Excellence, Magellan Health, AIDS, Research, Awareness, Pharmaceutical industry, Medical device, Magellan Rx Management, Magellan Health:, MAGELLAN RX MANAGEMENT, MAGELLAN HEALTH:

Through the program, clinical pharmacists partner with providers to manage complex cases by promoting best-practices for HIV treatment and closing care gaps.

Key Points: 
  • Through the program, clinical pharmacists partner with providers to manage complex cases by promoting best-practices for HIV treatment and closing care gaps.
  • For most patients, nearly perfect (>95 percent) adherence is necessary to achieve optimal viral suppression and clinical success.
  • Magellan Rx established a national ADAP Center of Excellence (COE) with a dedicated call center to provide timely service and continuity of care.
  • About Magellan Rx Management: Magellan Rx Management , a division of Magellan Health, Inc., is shaping the future of pharmacy.